ULTRAGENYX PHARMACEUTICAL INC. Restricted Cash and Cash Equivalents, Noncurrent
ULTRAGENYX PHARMACEUTICAL INC. (RARE) had Restricted Cash and Cash Equivalents, Noncurrent of $1.82 million as of 2018-06-30, per its 10-Q filed 2018-08-03.
Discontinued › Balance Sheet › Assets › Assets, Noncurrent
us-gaap:RestrictedCashAndCashEquivalentsNoncurrent · last filed 2018-08-03
- 2018-06-30: Restricted Cash and Cash Equivalents, Noncurrent $1.82M.
- 2018-03-31: Restricted Cash and Cash Equivalents, Noncurrent $1.93M.
- 2017-12-31: Restricted Cash and Cash Equivalents, Noncurrent $2.09M.
- 2017-09-30: Restricted Cash and Cash Equivalents, Noncurrent $1.80M.
| Period end | Restricted Cash and Cash Equivalents, Noncurrent |
|---|---|
| 2018-06-30 | $1.82M 10-Q · filed 2018-08-03 |
| 2018-03-31 | $1.93M 10-Q · filed 2018-05-08 |
| 2017-12-31 | $2.09M 10-Q · filed 2018-05-08 |
| 2017-09-30 | $1.80M 10-Q · filed 2017-11-03 |
| 2017-06-30 | $1.80M 10-Q · filed 2018-08-03 |
| 2017-03-31 | $2.00M 10-Q · filed 2018-05-08 |
| 2016-12-31 | $2.08M 10-K · filed 2018-02-21 |
| 2016-09-30 | $2.08M 10-Q · filed 2016-11-08 |
| 2016-06-30 | $2.35M 10-Q · filed 2016-08-09 |
| 2016-03-31 | $2.54M 10-Q · filed 2016-05-10 |
| 2015-12-31 | $2.13M 10-K · filed 2017-02-17 |
| 2015-09-30 | $912.00K 10-Q · filed 2015-11-10 |
| 2015-06-30 | $912.00K 10-Q · filed 2015-08-14 |
| 2015-03-31 | $1.03M 10-Q · filed 2015-05-12 |
| 2014-12-31 | $744.00K 10-K · filed 2016-02-26 |
| 2014-09-30 | $744.00K 10-Q · filed 2014-11-10 |
| 2014-06-30 | $744.00K 10-Q · filed 2014-08-11 |
| 2014-03-31 | $744.00K 10-Q · filed 2014-05-12 |
| 2013-12-31 | $451.00K 10-K · filed 2015-03-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |